Abiratas 250mg Tablet
Rx RequiredSalt Composition: Abiraterone Acetate
Expiry Date: 01/2028
Buy at $223.53
Inclusive of all taxes
120 Tablet in Bottle
About The Product
Prostate Cancer
Abiratas 250mg Tablet is a prescription-based medicine used in the treatment of cancer of the prostate gland. This anticancer medicine is also given with other medications as part of combination chemotherapy. It is given to adult men diagnosed with prostate cancer, which has spread to other parts of the body. Abiratas Tablet is usually given with steroid medication to lower the chances of side effects.
Description
Abiratas 250mg Tablet is given to treating Prostate Cancer patients. The active constituent of this medicine is Abiraterone Acetate.
It can be taken with or without food as per doctor's recommendation. The doctor will decide the necessary dose and how many times a patient has to take it.
This depends on the type of disease and it may change after some time. This medicine should not be given to women or children without consulting a healthcare expert.
As Abiratas Tablet has components like lactose and sodium, it is advised to inform your physician if you're lactose intolerant or on a salt-controlled diet. Taking Abiratas Tablet inappropriately or overdosing can result in severe side effects.
It may take some time to notice the benefits of this medicine but it is advised strictly not to stop taking it unless your doctor tells you to. It is important to inform your healthcare about all the medicines, including supplements and herbal medicines, you are taking before you start the treatment with this medicine.
Side Effects
The majority of the side effects experienced after taking Abiratas 250mg Tablet do not need any medical help as they do not appear with time. The human body starts adapting to the medicine. Consult your doctor if they become unmanageable.
Common side effects of Abiratas Tablet are mentioned below:
Vomiting and Nausea
Muscle twitches & cramps
Fatigue
Anemia
Frequent urinary tract infection
Diarrhea & Indigestion
High blood pressure
Cough
Swelling in legs or feet
Chest pain
Irregular heartbeat
bone fractures
blood in urine
How To Use
- Abiratas 250mg Tablet is a prescription-based anticancer drug that should be administered orally.
- It is advised to take this tablet after consulting your healthcare expert.
How It Works
Abiratas 250mg Tablet is an anticancer medication used for treating prostate cancer. This medicine works by preventing androgen (male hormone) production in males.
It inhibits an enzyme termed as CYP17 which is responsible for the production of androgen. Androgen is a hormone that helps in the multiplication of cancer cells.
This process slows down the growth rate of cancerous cells in prostate cancer.
Safety Advice
Missed Doses
- It is advised not to miss any scheduled dosage of Abiratas 250mg Tablet.
- In case you miss a dose, consult your doctor immediately.
- Don't overdose to compensate for the missed one.
- Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.
Quick Tips
Abiratas 250mg Tablet is usually taken with another medication known as prednisolone to avoid the unwanted side effects.
It is advised to always use effective birth control methods to avoid pregnancy while undergoing treatment with Abiratas 250mg Tablet.
It is crucial to monitor your liver function, blood pressure, and the level of potassium in your blood regularly when undergoing treatment with Abiratas 250mg Tablet.
FAQs
Abiratas 250mg Tablet is an anticancer medication used for treating prostate cancer.
This medicine works by preventing the production of androgen hormone and thereby inhibiting an enzyme responsible for the production of androgen.
Reference
Acharya M, Bernard A, Gonzalez M, Jiao J, De Vries R, Tran N. (2024).
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol.
69(6):1583-90. Charles J.
Ryan et al. (2025).
Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy. J Clin Oncol 28, 1481-1488(2010).
Goyal J, Antonarakis ES.(2024).Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol 23(7):1-14.
Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. (2024).
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol.
28(9):1481-8. Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.
(2024). Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
J Clin Oncol. 36(14):1389-1395.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
